Enanta Pharmaceuticals
ENTA
136 hedge funds and large institutions have $347M invested in Enanta Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 52 increasing their positions, 38 reducing their positions, and 19 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
151% more call options, than puts
Call options by funds: $554K | Put options by funds: $221K
37% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 19
37% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 38
17% more capital invested
Capital invested by funds: $296M → $347M (+$50.7M)
5% more funds holding
Funds holding: 129 → 136 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$12.8M |
| 2 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$8.07M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.85M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$5.81M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$5.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$22.1M |
| 2 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$12.5M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.45M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$7.45M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.71M |
ENTA Hedge Fund Activity: Q3 2016 in Review
136 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2016, worth a combined $347M — up 17% from $296M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ENTA positions and 19 closed out — a net gain of 7 holders — while 52 added to existing stakes and 38 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $12.8M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $22.1M sold.
- 136 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2016, up from 129 in Q2 2016.
- Funds reported $347M of Enanta Pharmaceuticals stock for Q3 2016, up 17% quarter-over-quarter.
- 26 funds opened new Enanta Pharmaceuticals positions in Q3 2016 and 19 closed out, a net change of +7 holders.
- The largest Enanta Pharmaceuticals buyer in Q3 2016 was Renaissance Technologies, an estimated $12.8M added.
- The largest Enanta Pharmaceuticals seller in Q3 2016 was Eagle Asset Management, an estimated $22.1M sold.
Based on aggregated 13F filings for Q3 2016.